Status:

TERMINATED

Intravenous Ferric Carboxymaltose (Ferinject®) With or Without Erythropoietin in Patients Undergoing Orthopaedic Surgery

Lead Sponsor:

University of Zurich

Collaborating Sponsors:

Vifor Pharma

Conditions:

Iron Deficiency Anemia

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Study Design: Single-centre, block randomised, blinded, controlled, phase IIIb, parallel group pilot study. Primary Objective: • To evaluate the effect of the administration of ferric carboxymaltose...

Detailed Description

TREATMENT: Patients will be randomised 1:1:1 to one of the following groups: Group I - Ferinject ® and EPO treatment group 25 patients will be randomised to the Ferinject and EPO treatment group. F...

Eligibility Criteria

Inclusion

  • \> 18 years of age and signed written informed consent
  • Patients scheduled to undergo major orthopaedic surgery (hip or knee arthroplasty or back surgery)
  • 10 g/dl \< Hb \< 13.0 g/dl for men and 10 g/dl \< Hb \< 12.0 g/dl for women, at screening ( 3 weeks prior to surgery)
  • Ferritin \< 100 μg/l or 100-300 with TSat \< 20%

Exclusion

  • Suspicion of iron overload (Ferritin \>300 μg/l or/and TSAT\>50%)
  • Active severe infection/inflammation (defined as serum CRP \> 20 mg/l) or diagnosed malignancy
  • Folate-and/or Vitamin B12 deficiency (according to local lab reference range)
  • Known history of hepatitis B/C or HIV-positive
  • Liver values 3 times higher than normal
  • Immunosuppressive or myelosuppressive therapy
  • A concurrent medical condition(s) that, in the view of the investigator, would prevent compliance or participation or jeopardize the health of the patients.
  • Pregnancy or lactation
  • Transfusion within 1 month prior to study inclusion, EPO treatment with in the last 4 weeks, any iron treatment within 4 weeks prior to the inclusion in the trail
  • Participation in any other therapeutic trial within the previous month
  • History of thromboembolic events in the family or the patient
  • Severe peripheral, coronary or carotid artery disease
  • Bodyweight \< 50 kg
  • Patients not able to understand the German language

Key Trial Info

Start Date :

May 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2012

Estimated Enrollment :

75 Patients enrolled

Trial Details

Trial ID

NCT00706667

Start Date

May 1 2008

End Date

December 1 2012

Last Update

June 20 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Zurich, Division of Anaesthesiology

Zurich, Canton of Zurich, Switzerland, 8091